Department of Radiology, University of Brescia, Brescia, Italy,
Eur Radiol. 2013 Dec;23(12):3450-5. doi: 10.1007/s00330-013-2965-0. Epub 2013 Jul 9.
To assess whether tumour heterogeneity, quantified by texture analysis (TA) on contrast-enhanced computed tomography (CECT), can predict response to chemotherapy in advanced non-small cell lung cancer (NSCLC).
Fifty-three CECT studies of patients with advanced NSCLC who had undergone first-line chemotherapy were retrospectively reviewed. Response to chemotherapy was evaluated according to RECIST1.1. Tumour uniformity was assessed by a TA method based on Laplacian of Gaussian filtering. The resulting parameters were correlated with treatment response and overall survival by multivariate analysis.
Thirty-one out of 53 patients were non-responders and 22 were responders. Average overall survival was 13 months (4-35), minimum follow-up was 12 months. In the adenocarcinoma group (n = 31), the product of tumour uniformity and grey level (GLU) was the unique independent variable correlating with treatment response. Dividing the GLU (range 8.5-46.6) into tertiles, lesions belonging to the second and the third tertiles had an 8.3-fold higher probability of treatment response compared with those in the first tertile. No association between texture features and response to treatment was observed in the non-adenocarcinoma group (n = 22). GL*U did not correlate with overall survival.
TA on CECT images in advanced lung adenocarcinoma provides an independent predictive indicator of response to first-line chemotherapy.
评估基于增强 CT(CECT)纹理分析(TA)量化的肿瘤异质性能否预测晚期非小细胞肺癌(NSCLC)的化疗反应。
回顾性分析了 53 例接受一线化疗的晚期 NSCLC 患者的 CECT 研究。根据 RECIST1.1 评估化疗反应。采用基于拉普拉斯高斯滤波的 TA 方法评估肿瘤均匀性。通过多变量分析,将得到的参数与治疗反应和总生存相关联。
53 例患者中,31 例为无反应者,22 例为有反应者。平均总生存期为 13 个月(4-35),最小随访时间为 12 个月。在腺癌组(n=31)中,肿瘤均匀性和灰度(GLU)的乘积是与治疗反应相关的唯一独立变量。将 GLU(范围 8.5-46.6)分为三分位数,第二和第三分位数的病变对治疗的反应概率是第一个分位数的 8.3 倍。在非腺癌组(n=22)中,未见纹理特征与治疗反应相关。GL*U 与总生存无相关性。
CECT 图像 TA 分析为晚期肺腺癌患者提供了一线化疗反应的独立预测指标。